Loading…
Foshan Yiying Hygiene Products Co., Ltd., a Chinese manufacturer of over-the-counter drug products, failed to conduct adequate finished product testing to verify that batches met final specifications, including identity and strength of active ingredients prior to release, in violation of 21 CFR 211.165(a). The facility's manufacturing methods, facilities, and controls did not conform to Current Good Manufacturing Practice (CGMP) regulations, rendering its drug products adulterated under the Federal Food, Drug, and Cosmetic Act. The FDA issued this warning letter on October 10, 2025, following the company's response to a records request issued on February 10, 2025.